

## INTELLECTUAL PROPERTY LAW SPECIALISTS

Caesar, Rivise, Bernstein, Cohen & Pokotilow is internationally recognized as a leading U.S. intellectual property law firm. Since 1926, Caesar Rivise has assisted companies and individual inventors around the globe in cultivating and protecting their intellectual property. Recognized by their



peers and clients as leaders of the intellectual property bar, the firm's lawyers have been named to be among the best in the nation and in Pennsylvania by *Best Lawyers in America*, *Chambers USA*, *America's Leading Business Lawyers*, and *Pennsylvania Super Lawyers*. For decades, the firm has received the highest possible peer review rating (AV) from Martindale Hubbell.

FOR MORE INFORMATION  
CONCERNING ANDA OR YOUR OTHER  
INTELLECTUAL PROPERTY NEEDS, CONTACT:



CAESAR, RIVISE, BERNSTEIN, COHEN & POKOTILOW, LTD.  
Intellectual Property, Computer and Information Technology Law

1635 Market Street 11th Floor  
Philadelphia, Pennsylvania 19103-2212  
Telephone: 215-567-2010 Fax 215-751-1142

[www.crbcp.com](http://www.crbcp.com)  
[anda@crbcp.com](mailto:anda@crbcp.com)

## ANDA LITIGATION




CAESAR, RIVISE, BERNSTEIN, COHEN & POKOTILOW, LTD.  
Intellectual Property, Computer and Information Technology Law



ANDA  
ANDA **WHOLE LOT MORE** <sup>SM</sup>



**CAESAR, RIVISE, BERNSTEIN, COHEN & POKOTILOW, LTD.**  
Intellectual Property, Computer and Information Technology Law



### ANDA EXPERIENCE MATTERS

In today's quickly changing, complex and high-stakes patent litigation environment, pharmaceutical companies need the ANDA legal expertise and industry know-how that is the hallmark of Caesar Rivise. Our attorneys are recognized internationally for their professional abilities and their commitment to quality service in all IP areas.


Caesar Rivise offers clients an exceptionally high level of litigation experience nationwide involving ANDAs containing Paragraph IV challenges to Orange Book listed patents. The firm has assisted pharmaceutical companies, especially generics, grow and prosper from ANDA litigation by bringing their drug products on the market. For example, the firm's efforts were instrumental in enabling the largest "at-risk" launch in pharmaceutical history (for a generic version of the blockbuster drug Plavix®), invalidating a patent for Razadyne®/Reminyl® and obtaining favorable settlements that are approved by appropriate regulatory authorities.

Caesar Rivise's extensive experience with ANDA litigation nationwide ensures cost effective services through every phase of ANDA litigation, including:

- Counseling Generics on ANDA Strategies, Product Design and Clearance
- Conducting Prior Art Searches
- Preparing Patent Opinions
- Drafting Paragraph IV Notice Letters
- Handling Concurrent Reexamination Proceedings
- Addressing Patent Related Antitrust Matters
- Counseling Generics on At-Risk Launches
- Preparing, Trying and Arguing Cases
- Appellate ANDA Practice
- Negotiating Successful Settlements

### GEOGRAPHIC SCOPE OF PRACTICE

- U.S. Patent and Trademark Office
- U.S. Copyright Office
- U.S. Federal Courts
- World Intellectual Property Organization
- Courts and Intellectual Property Offices in Over 45 Countries Around the World



### REPRESENTATIVE ANDA CASES

*Sanofi & BMS v. Apotex* (NY & Fed. Cir.) re blockbuster Plavix® (clopidogrel bisulfate) for cardiovascular conditions

*In re '318 Patent Litigation* (DE & Fed. Cir.) re Razadyne®/Reminyl® (galanthamine) for Alzheimer's

*AstraZeneca v. Apotex* (NY & Fed. Cir.) re block- buster Prilosec® (omeprazole) for acid reflux

*Genzyme v. Pentech Pharm./Cobrek* (IL) re Hectorol® (doxercaliferol) for secondary hyperparathyroidism

*Steifel v. Pentech Pharm./Cobrek* (IL) re Luxiq® (betamethasone valerate) and Olux® (clobetasol) for skin conditions

*Novartis v. Apotex* (NY) re Miacalcin® (calcitonin) for osteoporosis; Zaditor® (ketotifen) for itchy eyes

*Biovail v. Torpharm* (PA & IL) re Tiazac®/Cardizem CD® (diltiazem hydrochloride) for hypertension

*Eli Lilly & Co. v. InvaGen* (IN & NY) re Evista® (raloxifene) for women with osteoporosis

*Unigene & Upsher-Smith v. Apotex* (NY) re Fortical® (calcitonin) for osteoporosis

*Roche/Syntex & Allergan v. Apotex* (CA & Fed. Cir.) re Acular LS®/Acular® (ketorolac tromethamine) for eye inflammation

*Ferring v. Apotex* (NJ) re DDAVP® (desmopressin) for urinary conditions

*Glaxo v. Pharmadyne* (MD) re Zantac® (ranitidine hydrochloride) for heartburn

### CAESAR, RIVISE, BERNSTEIN, COHEN & POKOTILOW, LTD.

PATENTS, TRADEMARKS, COPYRIGHTS  
**ANDA Team**

11<sup>th</sup> Floor - Seven Penn Center - 1635 Market Street  
Philadelphia, PA 19103-2212  
Telephone: 215-567-2010  
Fax: 215-751-1142  
Email: anda@crbcp.com